510(k) · Cleared
ClearedT3 Platform Software
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Etiometry, Inc. · PPW Adjunctive Cardiovascular Status Indicator
Cleared on Jun 22, 2022 as substantially equivalent to DEN160020 (Flashback Technologies, Inc., 2016) and 1 other predicate after a 266-day review. Its family tree reaches back 12 generations to 1997. 12 later devices descend from it.
- Decided
- Jun 22, 2022
- Review
- 266 days
- Class
- Class II
- Product code
- PPW
- Recalls
- None
- Predicates
- 2
Its longest line of descent runs back 12 generations to K962603 (1997). 56 ancestors in all, the oldest K891104 (1989). 12 later devices descend from it, 3 citing it directly.
- Root · 12 generations backK962603 Masimo Set MS-1 Pulse Oximeter & the Lnop Series of Sensors & CablesMasimo Corp. · 1997
- 8 generations between
- 3 generations backK163065 T3 SoftwareEtiometry, Inc. · 2017
- 2 generations backK190273 T3 Platform softwareEtiometry, Inc. · 2019
- 1 generation backK202306 T3 Platform softwareEtiometry, Inc. · 2020
- This deviceK213230 T3 Platform SoftwareEtiometry, Inc. · 2022
- Descendant · cites it directly · 7 of its ownK222463 EchoGo Heart FailureUltromics Limited · 2022
- Descendant · 2 generations on · 2 of its ownK240860 EchoGo Amyloidosis (1.0)Ultromics Limited · 2024
- Descendant · cites it directly · 2 of its ownK223578 T3 Platform softwareEtiometry, Inc. · 2023
- Descendant · cites it directly · 2 of its ownK213423 T3 Platform softwareEtiometry, Inc. · 2023
- Descendant · 2 generations on · 1 of its ownK241479 Etiometry Platform (DAV 5.4 RAE 9.2)Etiometry, Inc. · 2025
Show all 12 generations
- Root · 12 generations backK962603 Masimo Set MS-1 Pulse Oximeter & the Lnop Series of Sensors & CablesMasimo Corp. · 1997
- 11 generations backK973887 Masimo Set MS-1P Pulse Oximeter and the Lnop Series of Sensors and…Masimo Corp. · 1998
- 10 generations backK982255 Model 2000 Pulse OximeterIvy Biomedical Systems, Inc. · 1998
- 9 generations backK991823 N-395 Pulse Oximeter, Model N-395Nellcor Puritan Bennett, Inc. · 1999
- 8 generations backK012451 Propaq Encore Models 202, 204, 206; Propaq CS Models 242, 244, 246Welch Allyn Protocol, Inc. · 2001
- 7 generations backK061993 Equivital, Model EQ-01Hidalgo Limited · 2006
- 6 generations backK081140 VisensiaObs Medical · 2008
- 5 generations backK110953 Visensia, Visensia with AlertObs Medical · 2011
- 4 generations backK152258 T3 SoftwareEtiometry, Inc. · 2016
- 3 generations backK163065 T3 SoftwareEtiometry, Inc. · 2017
- 2 generations backK190273 T3 Platform softwareEtiometry, Inc. · 2019
- 1 generation backK202306 T3 Platform softwareEtiometry, Inc. · 2020
- This deviceK213230 T3 Platform SoftwareEtiometry, Inc. · 2022
Showing 5 of 12 descendants. See all descendants
Descendants cleared per year
Most influential descendants
Showing 5 of 12 · See all- K222463EchoGo Heart FailureUltromics Limited · 2022 · cites it directly7descendants
- K240860EchoGo Amyloidosis (1.0)Ultromics Limited · 2024 · 2 generations on2descendants
- K223578T3 Platform softwareEtiometry, Inc. · 2023 · cites it directly2descendants
- K213423T3 Platform softwareEtiometry, Inc. · 2023 · cites it directly2descendants
- K241479Etiometry Platform (DAV 5.4 RAE 9.2)Etiometry, Inc. · 2025 · 2 generations on1descendant
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −12 | K962603 | Masimo Set MS-1 Pulse Oximeter & the Lnop Series of Sensors & Cables | Masimo Corp. | 1997 | — |
| −11 | K973887 | Masimo Set MS-1P Pulse Oximeter and the Lnop Series of Sensors and Cables | Masimo Corp. | 1998 | — |
| −10 | K982255 | Model 2000 Pulse Oximeter | Ivy Biomedical Systems, Inc. | 1998 | — |
| −9 | K991823 | N-395 Pulse Oximeter, Model N-395 | Nellcor Puritan Bennett, Inc. | 1999 | — |
| −8 | K012451 | Propaq Encore Models 202, 204, 206; Propaq CS Models 242, 244, 246 | Welch Allyn Protocol, Inc. | 2001 | — |
| −7 | K061993 | Equivital, Model EQ-01 | Hidalgo Limited | 2006 | — |
| −6 | K081140 | Visensia | Obs Medical | 2008 | — |
| −5 | K110953 | Visensia, Visensia with Alert | Obs Medical | 2011 | — |
| −4 | K152258 | T3 Software | Etiometry, Inc. | 2016 | — |
| −3 | K163065 | T3 Software | Etiometry, Inc. | 2017 | — |
| −2 | K190273 | T3 Platform software | Etiometry, Inc. | 2019 | — |
| −1 | K202306 | T3 Platform software | Etiometry, Inc. | 2020 | — |
| 0 (this device) | K213230 | T3 Platform Software | Etiometry, Inc. | 2022 | — |
| +1 | K222463 | EchoGo Heart Failure | Ultromics Limited | 2022 | — |
| +2 | K240860 | EchoGo Amyloidosis (1.0) | Ultromics Limited | 2024 | — |
| +1 | K223578 | T3 Platform software | Etiometry, Inc. | 2023 | — |
| +1 | K213423 | T3 Platform software | Etiometry, Inc. | 2023 | — |
| +2 | K241479 | Etiometry Platform (DAV 5.4 RAE 9.2) | Etiometry, Inc. | 2025 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1989 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 5 | 0 |
| 2001 | 4 | 0 |
| 2002 | 1 | 0 |
| 2003 | 3 | 0 |
| 2004 | 2 | 0 |
| 2005 | 2 | 0 |
| 2006 | 1 | 0 |
| 2009 | 1 | 0 |
| 2010 | 2 | 0 |
| 2012 | 1 | 0 |
| 2013 | 3 | 0 |
| 2014 | 1 | 0 |
| 2015 | 2 | 0 |
| 2016 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2022 | 1 | 0 |
| 2023 | 4 | 0 |
| 2024 | 2 | 0 |
| 2025 | 4 | 0 |
| 2026 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in PPW? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new PPW device
- #1 K241479 Etiometry Platform (DAV 5.4 RAE 9.2)score 15.7 · 14 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (2)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | DEN160020 | CipherOx CRI TabletSummary page 7…Table 97: Device Information K213230 Page 1 of 7 510(k) Summary 9.3 Predicate Devices The primary predicate device is the CipherOx CRI, cleared under DEN160020, and the supportive predicate device is the T3 Platform™ software featuring the T3 Data Aggregation & Visualization software modu… | 2016 |
| * | K202306 | T3 Platform softwareSummary page 7…tform™ software featuring the T3 Data Aggregation & Visualization software module version 5.0 and the T3 Risk Analytics Engine software module version 6.0, cleared under K202306. These predicates have not been subject to a design-related recall. No reference devices were used in this submission. 9.4 Devic… | 2020 |
What descends from it? (12)
See all 123 later devices cite it directly; ranked here by how many devices descend from each in turn.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 25 years and passes through 7 companies; a new generation was cleared every 1.7 years on median.
- 7 of the 56 ancestors have a recall of any class.
- Of its descendants, K222463 (Ultromics Limited, 2022) has gone furthest, with 7 descendants of its own.
- 1 other device also cites its predicate DEN160020.
How does its category compare?
All PPW devicesPPW Adjunctive Cardiovascular Status Indicator: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.
FDA decisions per year · PPW
2in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · PPW
Too few PPW 510(k)s in any year since 2007 to give a median.
Recalls per year · PPW
No recall names PPW since 2007.
Adverse event reports per year · PPW
No MAUDE report names PPW since 2007.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 1 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 1 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 0 |
| 2022 | 2 | — | 0 | 0 |
| 2023 | 1 | — | 0 | 0 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 2 | — | 0 | 0 |
| 2026 | 1 | — | 0 | — |
What is it indicated for?
The T3 Platform™ software features the T3 Data Aggregation & Visualization software module version 5.0 and the T3 Risk Analytics Engine software module version 8.0. The T3 Data Aggregation & Visualization software module is intended for the recording and display of multiple physiological parameters of the adult, pediatric, and neonatal patients from supported bedside devices. The software module is not intended for alarm notification or waveform display…
Read the full statement (879 words)
The T3 Platform™ software features the T3 Data Aggregation & Visualization software module version 5.0 and the T3 Risk Analytics Engine software module version 8.0.
The T3 Data Aggregation & Visualization software module is intended for the recording and display of multiple physiological parameters of the adult, pediatric, and neonatal patients from supported bedside devices. The software module is not intended for alarm notification or waveform display, nor is it intended to control any of the independent bedside devices to which it is connected. The software module is intended to be used by healthcare professionals for the following purposes:
• To remotely consult regarding a patient’s status, and
• To remotely review other standard or critical near real-time patient data in order to utilize this information to aid in clinical decisions and deliver patient care in a timely manner.
The T3 Data Aggregation & Visualization software module can display numeric physiologic data captured by other medical devices:
• Airway flow, volume, and pressure
• Arterial blood pressure (invasive and non-invasive, systolic, diastolic, and mean)
• Bispectral index (BIS, signal quality index, suppression ratio)
• Cardiac Index
• Cardiac output
• Central venous pressure
• Cerebral perfusion pressure
• End-tidal CO2
• Heart rate
• Heart rate variability
• Intracranial pressure
• Left atrium pressure
• Oxygen saturation (intravascular, regional, SpO2)
• Premature ventricular counted beats
• Pulmonary artery pressure (systolic, diastolic, and mean)
• Pulse pressure variation
• Pulse Rate
• Respiratory rate
• Right atrium pressure
• Temperature (rectal, esophageal, tympanic, blood, core, nasopharyngeal, skin)
• Umbilical arterial pressure (systolic, diastolic, and mean)
The T3 Data Aggregation & Visualization software module can display laboratory measurements including arterial and venous blood gases, complete blood count, and lactic acid. T3 Data Aggregation & Visualization software module can display information captured by the T3 Risk Analytics Engine software module.
The T3 Risk Analytics Engine software module calculates four indices: the IDO2 Index™ for inadequate delivery of oxygen, the IVCO2 Index™ for inadequate ventilation of carbon dioxide, the ACD Index™ for acidemia, and the HLA Index™ for hyperlactatemia.
The IDO2 Index™ is indicated for use by health care professionals with post-surgical patients 0 to 12 years of age and weighing 2 kg or more under intensive care. The IDO2 Index™ is derived by mathematical manipulations of the physiologic data and laboratory measurements received by the T3 Data Aggregation & Visualization software module. When the IDO2 Index™ is increasing, it means that there is an increasing risk of inadequate oxygen delivery and attention should be brought to the patient. The IDO2 Index™ presents partial quantitative information about the patient's cardiovascular condition, and no therapy or drugs can be administered based solely on the interpretation statements.
The IVCO2 Index™ is indicated for use by health care professionals with invasively ventilated patients 0 to 12 years of age and weighing 2 kg or more under intensive care. The IVCO2 Index™ is derived by mathematical manipulations of the physiologic data and laboratory measurements received by the T3 Data Aggregation and Visualization software module. When the IVCO2 Index™ is increasing, it means that there is an increasing risk of inadequate carbon dioxide ventilation and attention should be brought to the patient. The IVCO2 Index™ presents partial quantitative information about the patient's respiratory condition, and no therapy or drugs can be administered based solely on the interpretation statements.
The ACD Index™ is indicated for use by health care professionals with invasively ventilated patients 0 to 12 years of age and weighing 2 kg or more under intensive care. The ACD Index™ is derived by mathematical manipulations of the physiologic data and laboratory measurements received by the T3 Data Aggregation and Visualization software module. When the ACD Index™ is increasing, it means that there is an increasing risk of acidemia and attention should be brought to the patient. The ACD Index™ presents partial quantitative information about the patient's respiratory condition, and no therapy or drugs can be administered based solely on the interpretation statements.
The HLA Index™ is indicated for use by health care professionals with post-surgical patients 0 to 12 years of age and weighing 2 kg or more under intensive care. The HLA Index™ is derived by mathematical manipulations of the physiologic data and laboratory measurements received by the T3 Data Aggregation & Visualization software module. When the HLA Index™ is increasing, it means that there is an increasing risk of hyperlactatemia and attention should be brought to the patient. The HLA Index™ presents partial quantitative information about the patient's cardiovascular condition, and no therapy or drugs can be administered based solely on the interpretation statements.
WARNINGS:
• Do not use the T3 Platform software as an active patient monitoring system.
• Do not use the T3 Platform software to replace any part of the hospital's device monitoring.
• Do not rely on the T3 Platform software as the sole source of patient status information.
• Do not use any of the T3 Platform indices as a substitute for taking blood samples.
• The indices present qualitative and potentially imperfect information of the patient's condition and in certain scenarios, the indices may contradict each other. The primary data should be reviewed as part of standard patient evaluations and no decisions should be solely based on the indices.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K213230 · printed Nov 4, 2026
Cite this page
510(k) Report. “K213230: T3 Platform Software.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K213230
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026